Advertisement
GSK vs NVS
Which Stock Would AI Choose? GlaxoSmithKline (GSK) vs. Novartis (NVS) Stock Comparison
Key Takeaways
- Novartis (NVS) has delivered stronger year-to-date returns than GlaxoSmithKline (GSK) amid recent market activity, supported by robust quarterly results.
- Both companies maintain diversified pharmaceutical portfolios focused on specialty medicines, with GSK emphasizing vaccines and respiratory treatments while NVS prioritizes oncology and immunology.
- Recent performance for GSK reflects a temporary setback from a discontinued clinical program, offset by ongoing pipeline advancements and upcoming earnings.
- NVS reported better-than-expected second-quarter results in recent weeks, driving positive sentiment and reaffirmation of full-year guidance.
- Sector exposure to healthcare provides defensive characteristics for both stocks, though relative momentum favors NVS in the current environment.
- Market positioning highlights trade-offs between GSK’s valuation metrics and NVS’s scale and growth drivers in key therapeutic areas.
Introduction
GlaxoSmithKline (GSK) and Novartis (NVS) represent two major players in the global pharmaceutical industry, offering investors exposure to innovative drug development, established product portfolios, and steady dividend streams. This comparison examines their recent stock behavior, business fundamentals, and relative positioning within the healthcare sector. Institutional and retail investors seeking balanced exposure to large-cap biopharma names may find the analysis relevant for portfolio construction, sector rotation decisions, or evaluating defensive growth opportunities in a volatile market environment. The focus remains on observable trends and verifiable developments rather than forward projections.
GSK Overview and Recent Performance
GlaxoSmithKline (GSK) operates as a global biopharmaceutical company with core operations in vaccines, specialty medicines including oncology and respiratory products, and HIV treatments through its ViiV Healthcare joint venture. In recent market activity, the stock has traded near the middle of its 52-week range following a period of mixed performance. Year-to-date returns stand approximately in the mid-single digits, lagging broader market benchmarks in some periods. Sentiment in recent weeks was influenced by the company’s decision to halt development of an experimental chronic cough treatment after missing primary endpoints in late-stage trials. Pipeline updates in areas such as oncology and malaria candidates, along with regulatory progress on existing assets like Shingrix, have provided counterbalancing support. The company reaffirmed its 2026 guidance after a solid first quarter, with second-quarter results scheduled for release shortly.
NVS Overview and Recent Performance
Novartis (NVS) is a leading Swiss pharmaceutical company with significant presence in oncology, immunology, cardiovascular, and neuroscience therapies. The stock has exhibited stronger relative performance in recent market activity, posting double-digit year-to-date gains. Recent weeks featured positive momentum following the release of second-quarter results that exceeded analyst expectations, with net sales growth driven by priority brands such as Kisqali, Kesimpta, and Pluvicto. The company reaffirmed its full-year 2026 guidance despite anticipated one-time benefits reversing in the second half. Additional developments include regulatory approvals for new indications and strategic acquisitions to bolster the pipeline in areas like antibody-drug conjugates. Institutional interest and analyst commentary have reflected cautious optimism tied to execution on key growth drivers amid a competitive sector landscape.
Trending AI Robots
Tickeron maintains a curated Trending AI Robots section that highlights select AI trading bots from its extensive library of hundreds of automated strategies. These bots cover thousands of tickers across equities, with only those demonstrating strong alignment with prevailing market conditions, consistent historical statistics, and suitable risk parameters earning placement in the trending roster. Available bots span diverse trading styles, timeframes, performance metrics, and ticker sets, allowing users to review detailed backtested results and live signals before deployment. The platform emphasizes transparency in strategy parameters and outcomes to support informed evaluation by traders seeking algorithmic assistance.
Head-to-Head Comparison
GlaxoSmithKline (GSK) and Novartis (NVS) differ in scale, with NVS maintaining a substantially larger market capitalization. Business models overlap in pharmaceuticals yet diverge in emphasis: GSK derives meaningful revenue from vaccines and general medicines alongside specialty assets, whereas NVS concentrates more heavily on high-growth oncology and specialty franchises. Recent momentum has favored NVS following its earnings beat, while GSK navigated a clinical setback. Risk factors include patent dynamics and regulatory outcomes for both, though NVS’s broader late-stage pipeline offers additional catalysts. Sector exposure remains defensive for each, with healthcare demand providing relative stability compared to cyclical industries. Market sentiment currently reflects NVS’s execution strength against GSK’s more tempered near-term narrative, creating distinct trade-offs for investors balancing growth and value considerations.
Tickeron AI Verdict
Based on observable factors such as recent earnings consistency, pipeline visibility, and relative price behavior in the current environment, Tickeron’s AI would likely assign a probabilistic preference toward Novartis (NVS) over GlaxoSmithKline (GSK). Stronger year-to-date performance and confirmed guidance provide a foundation for trend stability, though both names carry sector-specific uncertainties that warrant ongoing monitoring.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a StrongBuy and NVS is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GSK’s FA Score shows that 0 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).
- GSK’s FA Score: 0 green, 5 red.
- NVS’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GSK’s TA Score shows that 7 TA indicator(s) are bullish while NVS’s TA Score has 5 bullish TA indicator(s).
- GSK’s TA Score: 7 bullish, 2 bearish.
- NVS’s TA Score: 5 bullish, 3 bearish.
Price Growth
GSK (@Pharmaceuticals: Major) experienced а +2.46% price change this week, while NVS (@Pharmaceuticals: Major) price change was +0.12% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.92%. For the same industry, the average monthly price growth was -1.73%, and the average quarterly price growth was +1.81%.
Reported Earning Dates
GSK is expected to report earnings on Oct 28, 2026.
NVS is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.92% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| GSK | NVS | GSK / NVS | |
| Capitalization | 106B | 295B | 36% |
| EBITDA | 9.68B | 22.5B | 43% |
| Gain YTD | 9.856 | 16.816 | 59% |
| P/E Ratio | 16.69 | 23.61 | 71% |
| Revenue | 33.2B | 56.7B | 59% |
| Total Cash | 3.11B | 7.69B | 40% |
| Total Debt | 18.2B | 49B | 37% |
GSK | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 64 | 63 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 69 Overvalued | 7 Undervalued | |
PROFIT vs RISK RATING 1..100 | 40 | 6 | |
SMR RATING 1..100 | 35 | 34 | |
PRICE GROWTH RATING 1..100 | 49 | 48 | |
P/E GROWTH RATING 1..100 | 54 | 22 | |
SEASONALITY SCORE 1..100 | 55 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (7) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (69). This means that NVS’s stock grew somewhat faster than GSK’s over the last 12 months.
NVS's Profit vs Risk Rating (6) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (40). This means that NVS’s stock grew somewhat faster than GSK’s over the last 12 months.
NVS's SMR Rating (34) in the Pharmaceuticals Major industry is in the same range as GSK (35). This means that NVS’s stock grew similarly to GSK’s over the last 12 months.
NVS's Price Growth Rating (48) in the Pharmaceuticals Major industry is in the same range as GSK (49). This means that NVS’s stock grew similarly to GSK’s over the last 12 months.
NVS's P/E Growth Rating (22) in the Pharmaceuticals Major industry is in the same range as GSK (54). This means that NVS’s stock grew similarly to GSK’s over the last 12 months.
| GSK | NVS | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 4 days ago 65% | 4 days ago 55% |
| Momentum ODDS (%) | 4 days ago 69% | 4 days ago 46% |
| MACD ODDS (%) | 4 days ago 77% | 4 days ago 36% |
| TrendWeek ODDS (%) | 4 days ago 65% | 4 days ago 53% |
| TrendMonth ODDS (%) | 4 days ago 59% | 4 days ago 50% |
| Advances ODDS (%) | 4 days ago 62% | 14 days ago 52% |
| Declines ODDS (%) | 8 days ago 54% | 7 days ago 45% |
| BollingerBands ODDS (%) | 4 days ago 43% | 4 days ago 32% |
| Aroon ODDS (%) | 4 days ago 61% | 4 days ago 48% |
Advertisement
GSK and
Correlation & Price change
A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.
| Ticker / NAME | Correlation To NVS | 1D Price Change % | ||
|---|---|---|---|---|
| NVS | 100% | +1.37% | ||
| GSK - NVS | 65% Loosely correlated | +1.51% | ||
| AMGN - NVS | 56% Loosely correlated | +1.51% | ||
| BMY - NVS | 55% Loosely correlated | +0.89% | ||
| MRK - NVS | 54% Loosely correlated | +0.16% | ||
| ABBV - NVS | 51% Loosely correlated | +0.89% | ||
More | ||||